You will be shown a claim related to the COVID-19 pandemic, and the abstract of a biomedical research paper. Each sentence from the abstract will be on a separate line. Your task is to return a JSON object with two fields:

- "verdict": The fact-checking verdict. If the information in the abstract supports the claim, write "SUPPORT". If the abstract contradicts the claim, write "CONTRADICT".
- "evidence": An array of sentences providing evidence for the verdict. Please copy all relevant sentences verbatim from the abstract.

For instance, if the model were given the claim "the COVID vaccine is safe for healthy adults", the output might be
{
  "verdict": "SUPPORT",
  "evidence": ["Our findings indicate that the risks of severe COVID vaccine side effects are low for healthy adults."]
}

Claim: elevated serum levels of inflammaging marker mir-146a are associated with clinical response to tocilizumab in covid-19 patients

Abstract:
Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems.
The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome.
In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging.
Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia.
In these serum samples, as well as in 29 age-and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR.
We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007).
Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008).
Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat.
{"verdict": "CONTRADICT", "evidence": ["We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007)."]}